Tablets & Capsules

TC1019

Issue link: https://www.e-digitaleditions.com/i/1173734

Contents of this Issue

Navigation

Page 53 of 67

44 October 2019 Tablets & Capsules (DCP). The tableting blends con- tained magnesium stearate as lubri- cant and croscarmellose sodium as superdisintegrant. The dry binders used were a well-known commer- cially available brand of copovi- done and Omyaphar m 50 0 -OG, a large-surface-area, porous min- eral excipient [5, 6]. The ingredi- ents were mixed in a WA B Tur- bula T10F mixer, and both placebo and 10 percent piroxicam-contain- ing tablets of 200 milligrams were manufactured at 15,000 tablets per hour in a Fette 1200i rotar y tab- let press. Hardness, friability, dis- integ ration time, and dissolution were measured according to Eur. Ph. using a Pharmatron MultiTest 50, an Er weka TAR 102, a Phar- matron DisiTest 50, and a Sotax AT7smart. Compactability. As shown in Fig- ures 2a and 2b, adding only piroxi- cam to the MCC- and lactose-based filler-binders negatively impacted compactability. For the MCC-based filler-binder, the piroxicam reduced tablet hardness by about 50 new- tons through the entire compression range tested. For the lactose-based filler-binder, the piroxicam reduced tablet hardness up to 50 newtons at lower compression forces and 75 new tons at higher compr es- sion forces. Adding piroxicam did not affect compactabilit y for the DCP-based f iller-binder (Fig ure 2c), although the tablets achieved a hardness of only 50 newtons at more than 10 kilonewtons of com- pression force, indicating that the compactability of the filler-binder alone is very low. Adding 5 percent dry binder to either the MCC- or lactose-based for mulations restored their com- pactability to the placebo level (Fig- ures 2a and 2b). Moreover, at high compression forces copovidone sig- nificantly improved the compacta- bilit y of a 10 percent piroxicam MCC-based formulation. For the DCP-based formulation, adding dry binders only marginally improved compactability (Figure 2c). Figure 2 Compactability of DC formulations containing 10% piroxicam with and without dry binders a. MCC-based formulations Hardness (newtons) 400 350 300 250 200 150 100 50 0 Main compression force (kilonewtons) MCC DC MCC DC + piroxicam MCC DC + piroxicam + 5% Omyapharm 500-OG MCC DC + piroxicam + 5% copovidone 3 5 7 9 11 13 15 17 b. Lactose-based formulations Lactose DC Lactose DC + piroxicam Lactose DC + piroxicam + 5% Omyapharm 500-OG Lactose DC + piroxicam + 5% copovidone Hardness (newtons) Main compression force (kilonewtons) 300 250 200 150 100 50 0 3 5 7 9 11 13 15 17 c. DCP-based formulations Hardness (newtons) Main compression force (kilonewtons) 120 100 80 60 40 20 0 3 5 7 9 11 13 15 17 DCP DC DCP DC + piroxicam DCP DC + piroxicam + 5% Omyapharm 500-OG DCP DC + piroxicam + 5% copovidone

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC1019